Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.47 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.44 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | CPN1 | P15169 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14632098 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11 | |
| SCHEMBL1468566 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11 | |
| SCHEMBL967296 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11 | |
| SCHEMBL15667928 | 0.89 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL1840824 | 0.89 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL16104131 | 0.88 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11 | |
| SCHEMBL966683 | 0.86 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11 | |
| SCHEMBL2875169 | 0.83 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11 | |
| SCHEMBL17786300 | 0.83 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11 | |
| SCHEMBL967276 | 0.82 | L3MBTL1 (0.49) | SLC6A2SLC6A4LMNAL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-26 | — | — | US | disclosed |
| EP-2842939-B1 | BENZAMIDE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9695118-B2 | Benzamide derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-3061749-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2842939-A1 | BENZAMIDE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20110021780-A1 | MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-27 | — | — | US | disclosed |
| EP-2269986-A1 | MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | NQO2, SDHA, CYP3A5 | SLC6A2 424/4885SLC6A4 485/4885SLC6A3 534/4885 |
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CYP3A5, HDAC6, BRD1 | SLC6A2 1338/4885SLC6A4 937/4885SLC6A3 1236/4885 |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | NQO2, SDHA, CYP3A5 | SLC6A2 424/4885SLC6A4 485/4885SLC6A3 534/4885 |
| US-20110021780-A1 | MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR | PDCD2L, NOTUM, OXA1L | SLC6A2 4872/4885SLC6A4 4186/4885SLC6A3 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.